Develops precision oncology therapies for genetically defined cancers, focusing on synthetic lethality.
Repare Therapeutics Inc. is a clinical-stage precision oncology company operating in Canada and the United States, pioneering the discovery and development of therapeutics through its innovative synthetic lethality approach. At the heart of its research is SNIPRx, a proprietary, genome-wide platform that integrates CRISPR technology. This platform enables Repare Therapeutics to systematically identify and advance highly targeted cancer therapies, with a specific focus on genomic instability and DNA damage repair mechanisms.
The company's flagship product candidate, RP-3500, represents an oral small molecule inhibitor designed for the treatment of solid tumors characterized by specific genomic alterations in DNA damage repair pathways. Repare Therapeutics is also advancing RP-6306 through Phase I clinical trials, targeting tumors associated with genetic alterations such as CCNE1 amplification. Additionally, the Polymerase Theta program addresses synthetic lethality targets linked to BRCA mutations and other genomic irregularities, further expanding the company's therapeutic pipeline.
Founded in 2016 and headquartered in Montreal, Canada, Repare Therapeutics continues to push the boundaries of oncology research and drug development. With a strong commitment to leveraging cutting-edge technologies and genomic insights, the company aims to deliver novel treatments that address unmet needs in cancer care, ultimately improving outcomes for patients worldwide.